Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elafibranor 80 mg in Primary Biliary Cholangitis: Double-blind Placebo-Controlled Study with Open-label Extension
2019-004941-34Phase 3Active
- Sponsor
- Ipsen
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in primary biliary cholangitis (PBC) comparing Elafibranor 80 mg with Placebo (2 arms). Primary endpoint: Primary response at week 52. Started Aug 2020; status: active.
02
Drugs
elafibranor
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on 2019-004941-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004941-34.